Skip to main content
. 2022 Apr 21;13(3):e00269-22. doi: 10.1128/mbio.00269-22

TABLE 1.

Regimens and viral load at the final time point for all patientsa,b

Patient No. of time points 1st-line regimen Time since initiation of 1st-line treatment (yrs) 2nd-line regimen Viral load at final time point (copies/mL)
15664 6 d4T, 3TC, FTC 6.2 LPV/r, TDF, FTC 28,655
16207 5 d4T, 3TC, NVP 5.9 LPV/r, TDF, FTC 56,660
22763 8 d4T, 3TC, EFV 6.2 LPV/r, TDF, 3TC 15,017
22828 6 d4T, 3TC, NVP 6.4 LPV/r, TDF, 3TC/FTC 947
26892 7 d4T, 3TC, EFV 6 LPV/r, TDF, FTC 12,221
28545 5 TDF, FTC, EFV 1.3 LPV/r, AZT, 3TC 12,964
29447 4 TDF, FTC, EFV 2.8 LPV/r, TDF, FTC 64,362
47939 3 d4T, 3TC, EFV 10.1 LPV/r, AZT, 3TC/FTC 6,328
a

Patients initiated and maintained 1st-line regimens for between 1 and 10 years before being switched to 2nd-line regimens as part of the TasP trial. Eight of the nine patients were failing 2nd-line regimens at the final time point.

b

NRTI: d4T, stavudine; 3TC, lamivudine; TDF, tenofovir; FTC, emtricitabine; AZT, zidovudine. NNRTI: EFV, efavirenz; NVP, nevirapine. PI: LPV/r, lopinavir/ritonavir.